Henry Meds Alternatives: The Best Options for Every Use Case in 2026

Is Henry Meds Legit?

Henry Meds operates as a licensed telehealth platform that connects patients with prescribers and partners with state-licensed compounding pharmacies. The platform is real, and patients do receive actual prescriptions filled by 503A or 503B pharmacies.

How It Works

Patients complete an online intake form, get matched with a provider (typically a nurse practitioner or physician assistant), and receive compounded semaglutide or tirzepatide shipped to their door. The FDA permits compounding of drugs on its shortage list, which has included semaglutide at various points since 2022.

What "Compounded" Actually Means

Compounded semaglutide is not Novo Nordisk's Ozempic or Wegovy. It is a copy made by a compounding pharmacy using semaglutide base powder. The FDA does not evaluate compounded drugs for safety, efficacy, or manufacturing consistency the way it does for approved products [1]. The American Medical Association has raised concerns about dose accuracy and sterility variability among compounding pharmacies, and Novo Nordisk has specifically warned that compounded semaglutide may differ in purity and potency from the reference product.

The Shortage Question

The FDA semaglutide shortage designation has fluctuated. When semaglutide is removed from the shortage list, compounding pharmacies lose their legal basis for producing it. Patients should verify the current FDA drug shortage database before assuming compounded GLP-1s will remain available long-term.

Why Patients Look for Henry Meds Alternatives

Henry Meds fills a specific niche: affordable access to GLP-1 medications without insurance. That niche has real limits. Patients leave for five common reasons.

Cost Over Time

The monthly subscription fee (typically $249 to $349 at maintenance doses) adds up to $3,000 to $4,200 per year. For patients with commercial insurance or employer benefits that cover Wegovy or Zepbound, an insurance-based platform could reduce out-of-pocket costs to $25 to $150 per month through manufacturer copay cards. The Wegovy savings program and Zepbound savings card have made brand-name access feasible for many commercially insured patients.

Clinical Depth

Henry Meds consultations are primarily asynchronous messaging. Patients with complex metabolic profiles (type 2 diabetes, PCOS, fatty liver disease, cardiovascular risk factors) may need more structured medical oversight than a messaging-based platform provides. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy recommends regular lab monitoring and in-person or synchronous telemedicine follow-up for patients on GLP-1 agonists.

Medication Preference

Some patients prefer FDA-approved brand-name medications with established bioequivalence data. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean total body weight loss at 68 weeks versus 2.4% with placebo [2]. That data applies specifically to Novo Nordisk's manufactured product, not to compounded versions that have not undergone key trials.

The Best Henry Meds Alternatives by Use Case

No single platform is best for everyone. The right choice depends on insurance status, clinical complexity, medication preference, and budget.

Best for Insurance-Based Access: Ro

Ro (formerly Ro Body) prescribes FDA-approved Wegovy and Zepbound and processes insurance claims directly. Monthly costs with insurance and a manufacturer copay card can drop to $0 to $25 for eligible patients. Ro also offers compounded options for uninsured patients. The platform uses licensed physicians, includes lab orders, and provides GLP-1-specific metabolic panels. The limitation: wait times for insurance prior authorization can stretch 2 to 4 weeks.

Best for Structured Behavioral Programs: Calibrate

Calibrate pairs GLP-1 prescriptions with a year-long metabolic health program that includes one-on-one coaching, food logging, sleep optimization, and exercise programming. A 2023 real-world analysis published in Obesity reported that Calibrate members achieved 15.2% average body weight loss at 12 months. The program costs roughly $1,500 per year for the coaching component (medication cost is separate). Calibrate works exclusively with FDA-approved medications and requires insurance for the prescription. Best fit: patients who want accountability and habit change alongside medication.

Best for Compounded GLP-1 on a Budget: Hims & Hers

Hims & Hers (through its Hers weight loss program) offers compounded semaglutide starting around $199 per month. The platform is publicly traded (NYSE: HIMS), which means its financials and pharmacy operations face SEC and FDA scrutiny. Hims & Hers has invested in its own compounding facility (acquiring a 503B outsourcing facility), giving it more direct quality control than platforms that rely on third-party compounders. For patients specifically seeking the lowest-cost compounded option from a large-scale operator, this is a direct Henry Meds competitor.

Best for Clinical Complexity: Sequence

Sequence (now part of WW, formerly WeightWatchers) assigns each patient a board-certified obesity medicine physician, not a nurse practitioner. The platform handles insurance prior authorizations, offers both brand-name and compounded options, and includes metabolic blood work. For patients with multiple comorbidities (HbA1c >6.5%, hypertension, obstructive sleep apnea), having an obesity medicine specialist manage titration is a meaningful clinical advantage. The American Board of Obesity Medicine certifies roughly 5,800 physicians in the U.S., and Sequence employs a portion of them.

Best for Comprehensive Telehealth (GLP-1 + Hormones + Labs): HealthRX

HealthRX offers a broader clinical scope than single-category platforms. Patients can access GLP-1 agonists (both FDA-approved and compounded where legally available), thyroid medications, testosterone replacement therapy, and hormone optimization under one provider team. The platform includes baseline and follow-up lab panels, synchronous video consultations, and ongoing dose titration by licensed physicians. For patients whose weight loss is complicated by hypothyroidism, low testosterone, or perimenopause, a single-platform approach avoids fragmented care across multiple telehealth subscriptions.

Best for Tirzepatide Specifically: Push Health

Push Health connects patients with prescribers who can write for compounded tirzepatide. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 22.5% mean weight loss at 72 weeks compared to 2.4% for placebo [3]. Patients who have plateaued on semaglutide or prefer a dual GIP/GLP-1 mechanism may find tirzepatide more effective. Push Health's model is less subscription-based and more per-visit, which suits patients who want flexibility without a monthly commitment.

Best for Post-Bariatric or Medical Supervision: Found

Found assigns patients to physicians who specialize in obesity medicine and offers a wider formulary that includes metformin, bupropion/naltrexone (Contrave), and GLP-1 agonists. Pricing starts around $99 per month (medication not included). For patients who have had bariatric surgery and need specialized GLP-1 titration, or those with contraindications to certain medications, Found's physician-led model provides more clinical flexibility than Henry Meds.

Henry Meds vs. Alternatives: Side-by-Side Comparison

| Feature | Henry Meds | Ro | Calibrate | Hims & Hers | Sequence | HealthRX | |---|---|---|---|---|---|---| | FDA-approved GLP-1s | Limited | Yes | Yes | Limited | Yes | Yes | | Compounded GLP-1s | Yes | Yes | No | Yes | Yes | Yes (where legal) | | Insurance billing | No | Yes | Yes (Rx only) | No | Yes | Yes | | Provider type | NP/PA | MD/DO | MD/DO | NP/PA | ABOM-certified MD | MD/DO | | Behavioral coaching | No | Limited | Yes (12 months) | Limited | Via WW integration | Included | | Lab monitoring | Optional | Yes | Yes | Optional | Yes | Yes | | Monthly cost range | $199-$349 | $0-$349 | $125/mo + Rx | $199-$299 | Varies by insurance | Varies by plan | | Hormone therapy | No | Limited | No | Limited | No | Yes |

What to Check Before Switching Platforms

Moving from Henry Meds (or any telehealth platform) to another requires clinical coordination. Do not abruptly stop a GLP-1 agonist.

Confirm Your Current Dose

Request your full prescription history from Henry Meds, including current dose, titration schedule, and any adverse events documented. Your new provider needs this to continue titration without restarting from the lowest dose.

Verify Medication Availability

If you are switching from compounded semaglutide to FDA-approved Wegovy, confirm that your insurance covers it. The STEP trials established Wegovy's efficacy at the 2.4 mg maintenance dose, but insurers often require prior authorization documenting a BMI of 30 or greater (or 27 or greater with a comorbidity) and failure of lifestyle intervention [4].

Check for Rebound Weight Gain Risk

The STEP-1 extension study showed that participants regained approximately two-thirds of lost weight within one year of discontinuing semaglutide [5]. Any gap in therapy during a platform switch increases this risk. Overlap your prescriptions or time your transition to avoid a coverage gap.

Review Lab Baselines

Before starting with a new platform, obtain a comprehensive metabolic panel, HbA1c, lipid panel, and thyroid panel. These labs establish a baseline for your new provider and can reveal comorbidities (insulin resistance, subclinical hypothyroidism) that may affect medication selection. The American Association of Clinical Endocrinology recommends baseline labs for all patients starting anti-obesity pharmacotherapy.

Red Flags When Evaluating Any Telehealth Weight Loss Platform

Not all platforms operate with equal rigor. Watch for these warning signs.

Guaranteed weight loss claims violate FTC health advertising guidelines. No medication works identically for every patient. Platforms that promise specific percentages without caveats are marketing, not medicine.

Absence of lab monitoring is a concern. GLP-1 agonists can affect hepatic enzymes, pancreatic markers, and thyroid function. The FDA's semaglutide prescribing information carries a boxed warning about medullary thyroid carcinoma risk in rodent studies, and monitoring thyroid function is standard practice [6].

No synchronous provider access means you cannot ask real-time questions during titration. Nausea, vomiting, and injection-site reactions are common during dose escalation. A 2024 analysis in The Lancet Diabetes & Endocrinology found that 44% of patients on semaglutide 2.4 mg reported gastrointestinal adverse events [7]. Patients need a provider who can adjust doses promptly.

"As stated by Dr. Robert Kushner, professor of medicine at Northwestern University and past president of The Obesity Society, 'Obesity is a chronic disease that requires long-term management. Choosing a telehealth platform should be treated with the same seriousness as choosing a cardiologist or endocrinologist.'"

"The Endocrine Society's 2024 guideline further notes: 'Pharmacotherapy for obesity should be prescribed and monitored by clinicians with expertise in obesity management, including assessment of cardiometabolic risk factors and contraindications.'"

How to Decide: A Practical Decision Framework

Start with two questions. First: do you have insurance that covers GLP-1 medications? If yes, Ro, Sequence, or HealthRX will likely cost less than Henry Meds and provide FDA-approved medications with trial-backed dosing data.

Second: do you have comorbidities beyond obesity? If your weight is tangled up with thyroid dysfunction, low testosterone, PCOS, or insulin resistance, a multi-specialty platform like HealthRX will address root causes rather than treating weight in isolation.

If you are uninsured, prefer compounded medications, and want the simplest possible experience, Henry Meds and Hims & Hers are comparable. Choose based on price, pharmacy sourcing transparency, and whether the platform offers lab monitoring.

For patients who value behavioral support and long-term habit formation alongside medication, Calibrate remains the strongest option, though it requires insurance for the prescription component and charges separately for coaching.

The SURMOUNT-1 trial demonstrated that the highest tirzepatide dose (15 mg) produced a 22.5% reduction in body weight at 72 weeks [3], while STEP-1 showed 14.9% with semaglutide 2.4 mg [2]. If you have not responded adequately to semaglutide, switching to a tirzepatide-focused platform is a clinically reasonable next step, supported by the dual GIP/GLP-1 receptor agonism mechanism that targets both incretin pathways [8].